All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.
Guselkumab vs fumaric acid esters for plaque psoriasis: Results from POLARIS trial
By Ella Dixon
|
Results from the phase III POLARIS trial, comparing guselkumab (GUS) with fumaric acid esters (FAE) in systemic treatment-naïve patients with moderate-to-severe plaque psoriasis, have been published in British Journal of Dermatology by Thaci et al.1 The trial assessed long-term safety and efficacy of GUS, as well as the durability of responses after stopping GUS treatment.1
|
| Key learnings: |
|
At Week 32, 78% and 90% of patients treated with GUS achieved 75% improvement in Psoriasis Area and Severity Index (PASI 75) and PASI 90, compared with 12% and 24% of FAE-treated patients, respectively. |
|
At Week 56, 91% of GUS-treated patients maintained PASI 90 response vs 50% of FAE-treated patients. PASI 90 response was also achieved by 80% of patients who switched from FAE to GUS at Week 32. |
|
47% of GUS-GUS withdrawal patients and 25% of FAE-GUS withdrawal patients maintained a PASI score ≤5 at Week 100. |
| Incidence of adverse events and treatment discontinuation was lower in both the GUS and switched to GUS groups compared with the FAE group. |
| In this study, GUS demonstrated superior long-term efficacy and safety compared with FAE for systemic treatment-naïve patients, suggesting potential as a preferred first-line systemic therapy. |
- Thaçi D, Pinter A, Sebastian M, et al. Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2024;191:36-48. DOI: 10.1093/bjd/ljad523
More about...
Your opinion matters
8 votes - 68 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox